New Stock News | New Bridge Biology submits listing application to Hong Kong Stock Exchange, mainly focusing on the development of independently researched and innovative precision immune cancer drugs.

Zhijing Finance APP learned that according to the disclosure of the Hong Kong Stock Exchange on October 31, New Bridge Biotech has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors.